Evaluation of direct medical costs of hospitalization for febrile neutropenia-Reference-Cited by-同舟云学术

Evaluation of direct medical costs of hospitalization for febrile neutropenia

Published:2010-02-01 Issue:3 Volume:116 Page:742-748
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Lathia Nina,Mittmann Nicole,DeAngelis Carlo,Knowles Sandra,Cheung Matthew,Piliotis Eugenia,Shear Neil,Walker Scott

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference20 articles.

1. Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management;Crawford;Cancer.,2004

2. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer;Hughes;Clin Infect Dis.,2002

3. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia;Bodey;Ann Intern Med.,1966

4. Planned progressive antimicrobial therapy in neutropenic patients;Viscoli;Br J Haematol.,1998

5. National Cancer Institute of Canada. Comparison of Cancer in Canada from 1987 to 1997. Available at: www.incc.cancer.ca/ncic/internet/standard/0,3621,84658243_85787780_91036744_langId-en,00.html Accessed September 28, 2007.

Cited by 68 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Economic implications of step-down outpatient management for fever and neutropenia episodes in pediatric cancer patients: a cost minimization analysis;BMC Health Services Research;2024-08-24

2. Ibrutinib Plus RCHOP versus RCHOP Only in Young Patients with Activated B-Cell-like Diffuse Large B-Cell Lymphoma (ABC-DLBCL): A Cost-Effectiveness Analysis;Current Oncology;2023-12-15

3. Cost-Effectiveness Analysis of Frontline Polatuzumab-Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone and/or Second-Line Chimeric Antigen Receptor T-Cell Therapy Versus Standard of Care for Treatment of Patients With Intermediate- to High-Risk Diffuse Large B-Cell Lymphoma;Journal of Clinical Oncology;2023-03-10

4. Effectiveness and Safety of Filgrastim (Neupogen™) versus Filgrastim-aafi (Nivestim™) in Primary Prophylaxis of Chemotherapy-Induced Febrile Neutropenia: An Observational Cohort Study;Drugs - Real World Outcomes;2022-09-07

5. Adherence to practice guidelines for the management of febrile neutropenia in patients undergoing hematopoietic stem cell transplantation: An observational study in a referral center in Iran;Journal of Oncology Pharmacy Practice;2022-04-07